DE60134021D1 - Pharmazeutische zubereitungen zur angiogenese-therapie - Google Patents

Pharmazeutische zubereitungen zur angiogenese-therapie

Info

Publication number
DE60134021D1
DE60134021D1 DE60134021T DE60134021T DE60134021D1 DE 60134021 D1 DE60134021 D1 DE 60134021D1 DE 60134021 T DE60134021 T DE 60134021T DE 60134021 T DE60134021 T DE 60134021T DE 60134021 D1 DE60134021 D1 DE 60134021D1
Authority
DE
Germany
Prior art keywords
angiogenic
gene
effect
contain
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60134021T
Other languages
English (en)
Inventor
Ryuichi Morishita
Hiromi Koike
Tadashi Tanabe
Motokuni Aoki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morishita Ryuichi Suita-Shi Osaka Jp
Anges Inc
Original Assignee
Anges MG Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges MG Inc filed Critical Anges MG Inc
Application granted granted Critical
Publication of DE60134021D1 publication Critical patent/DE60134021D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
DE60134021T 2000-06-27 2001-06-27 Pharmazeutische zubereitungen zur angiogenese-therapie Expired - Lifetime DE60134021D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000192480 2000-06-27
JP2000388624 2000-12-21
PCT/JP2001/005514 WO2002000258A1 (fr) 2000-06-27 2001-06-27 Compositions medicales de therapie angiogenique

Publications (1)

Publication Number Publication Date
DE60134021D1 true DE60134021D1 (de) 2008-06-26

Family

ID=26594742

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60134021T Expired - Lifetime DE60134021D1 (de) 2000-06-27 2001-06-27 Pharmazeutische zubereitungen zur angiogenese-therapie

Country Status (10)

Country Link
US (2) US20030171287A1 (de)
EP (2) EP1889633B1 (de)
KR (1) KR100798566B1 (de)
CN (1) CN1274365C (de)
AT (2) ATE530197T1 (de)
AU (2) AU2001266338B8 (de)
CA (1) CA2413768A1 (de)
DE (1) DE60134021D1 (de)
NZ (1) NZ523613A (de)
WO (1) WO2002000258A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU778826B2 (en) * 1999-10-29 2004-12-23 Anges Mg, Inc. Gene therapy for diabetic ischemic disease
US20050260582A1 (en) * 2001-02-13 2005-11-24 Hirofumi Kai Cell proliferation inhibitors comprising ets transcription factor or gene encoding the same
KR100562824B1 (ko) * 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
DE60333476D1 (de) * 2002-12-02 2010-09-02 Anges Mg Inc Zusammensetzungen zur behandlung oder prävention von angiogenese-abhängigen symptomen
US20070293447A1 (en) * 2003-08-29 2007-12-20 Yasuo Kunugiza Gene Therapy for Skin Disorders Using Needleless Syringes
WO2005084700A1 (en) * 2004-03-09 2005-09-15 Tohoku Technoarch Co., Ltd. An agent for promoting induction of vascular differentiation, comprising hepatocyte growth factor
PL1750862T3 (pl) 2004-06-04 2011-06-30 Teva Pharma Kompozycja farmaceutyczna zawierająca irbesartan
US7608416B2 (en) * 2004-12-07 2009-10-27 The Trustees Of The University Of Pennsylvania Targeting mPGES-1 as a treatment for inflammation which avoids cardiovascular risk
US7252834B2 (en) * 2005-04-25 2007-08-07 Clemson University Research Foundation (Curf) Elastin stabilization of connective tissue
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
JP2011513220A (ja) * 2008-02-21 2011-04-28 ヴァトリックス・メディカル・インコーポレーテッド デリバリービヒクルと組み合わせた結合組織安定剤の適用による動脈瘤の処置
ES2556711T3 (es) * 2008-04-09 2016-01-19 Viromed Co., Ltd. Formulaciones liofilizadas de ADN para el aumento de la expresión del ADN plasmídico
JP5725489B2 (ja) 2008-06-27 2015-05-27 公立大学法人大阪市立大学 医療用組成物および医療用キット
US20100016833A1 (en) * 2008-07-15 2010-01-21 Ogle Matthew F Devices for the Treatment of Vascular Aneurysm
US20100119605A1 (en) * 2008-11-12 2010-05-13 Isenburg Jason C Compositions for tissue stabilization
US8496911B2 (en) * 2009-07-29 2013-07-30 Vatrix CHF, Inc. Tissue stabilization for heart failure
CN102573924A (zh) * 2009-08-31 2012-07-11 福田惠一 血管生成疗法用医药组合物
US20110218517A1 (en) * 2009-10-09 2011-09-08 Ogle Matthew F In vivo chemical stabilization of vulnerable plaque
US8444624B2 (en) 2009-10-19 2013-05-21 Vatrix Medical, Inc. Vascular medical devices with sealing elements and procedures for the treatment of isolated vessel sections
US8911468B2 (en) 2011-01-31 2014-12-16 Vatrix Medical, Inc. Devices, therapeutic compositions and corresponding percutaneous treatment methods for aortic dissection
JP2014516695A (ja) 2011-05-18 2014-07-17 バトリックス・メディカル・インコーポレイテッド 血管安定化用被覆バルーン
US9283241B2 (en) 2012-07-10 2016-03-15 Clemson University Treatment to render implants resistant to diabetes
SG11201602452SA (en) 2013-10-22 2016-05-30 Viromed Co Ltd Composition for preventing or treating amyotrophic lateral sclerosis using two or more isoforms of hepatocyte growth factor
ES2705069T3 (es) 2014-06-12 2019-03-21 Tx Medic Ab Uso de sulfato de dextrano que tiene un peso molecular promedio inferior a 10000 da para inducir angiogénesis en un sujeto
AU2019305221A1 (en) 2018-07-19 2021-02-18 Helixmith Co., Ltd. Lyophilized pharmaceutical compositions for naked DNA gene therapy
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995030013A1 (fr) 1994-04-28 1995-11-09 Tadashi Tanabe Prostacycline-synthase d'origine humaine
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
JP3058828B2 (ja) * 1996-03-15 2000-07-04 株式会社巴川製紙所 電子写真トナー用ポリエステル系樹脂、該樹脂の製造方法及び該樹脂を用いた電子写真用トナー
US5785965A (en) * 1996-05-15 1998-07-28 The Board Of Trustees Of The Leland Stanford Junior Univ. VEGF gene transfer into endothelial cells for vascular prosthesis
US20030219380A1 (en) * 1997-11-07 2003-11-27 Annie Fong Method of determining an efficacious dose of a drug
AUPP459998A0 (en) * 1998-07-09 1998-07-30 Monash University Modulation of haemopoietic cell activity and inflammation via the ets-1 gene and agents useful for same
DE19940012A1 (de) 1999-08-24 2001-03-08 Karin Faerber Neues Mittel aus mindestens zwei Komponenten, das zum einen Gefäßneubildung (Neoangiogense) induziert des weiteren jedoch auch Gefäßverschlüsse (Restenosen) verhindert, das Verfahren seiner Herstellung und seine Verwendung
JP2001199903A (ja) * 1999-11-09 2001-07-24 Eizo Mori 核酸含有複合体
AU2001236886A1 (en) * 2000-02-09 2001-08-20 Connetics Corporation Use of relaxin to treat diseases related to vasoconstriction
US6533541B1 (en) 2001-12-04 2003-03-18 Honeywell International, Inc. High energy particle arrestor for air turbine starters

Also Published As

Publication number Publication date
AU2001266338B2 (en) 2006-11-09
EP1300158B1 (de) 2008-05-14
EP1889633A1 (de) 2008-02-20
US20030171287A1 (en) 2003-09-11
EP1889633B1 (de) 2011-10-26
NZ523613A (en) 2005-02-25
EP1300158B9 (de) 2008-11-19
KR20030014391A (ko) 2003-02-17
WO2002000258A8 (fr) 2003-01-23
KR100798566B1 (ko) 2008-01-28
CN1274365C (zh) 2006-09-13
WO2002000258A1 (fr) 2002-01-03
US7994151B2 (en) 2011-08-09
CN1446105A (zh) 2003-10-01
AU2001266338B8 (en) 2006-12-14
ATE530197T1 (de) 2011-11-15
CA2413768A1 (en) 2002-01-03
EP1300158A1 (de) 2003-04-09
ATE395071T1 (de) 2008-05-15
EP1300158A4 (de) 2005-04-13
US20100240735A1 (en) 2010-09-23
AU6633801A (en) 2002-01-08

Similar Documents

Publication Publication Date Title
ATE395071T1 (de) Pharmazeutische zubereitungen zur angiogenese- therapie
ATE270544T1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
ZA200405657B (en) Formulation & dosage form for the controlled delivery of therapeutic agents.
MY118151A (en) Pharmaceutical formulations containing voriconazole.
FR11C0017I2 (fr) Utilisation de spinosad ou d'une formulation comprennant spinosad
ATE554750T1 (de) Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
ATE293995T1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
NZ527157A (en) Compositions for delivering bisphosphonates
NO20042739L (no) Farmasoytiske sammensetninger av 5,6,14-triazatetracyklo(10.3.1.0(2,11).0(4,9))-heksadeca-2(11)3,5,7,9-pentan
ATE224717T1 (de) Oral anzuwendende arzneizubereitungen enthaltend eine benzhydrylpiperazine und eine zyklodextrin
DK1350511T3 (da) Medicinsk sammensætning indeholdende aspirin
ID18079A (id) Komposisi farmasi yang mengandung bahan pemercepat osteogenesis
EA200501697A1 (ru) Дозируемая форма, содержащая пантопразол в качестве активного ингредиента
BR9608392A (pt) Preparação multiparticulada de liberação controlada e forma de dosagem em tablete.
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
EP1273301A3 (de) Pharmazeutische Zubereitungen, Wirkstoffe enthaltend, die sich für unerlaubte Verabreichung bieten
EP2327784A3 (de) Nukleinsäuren zur Hemmung der Expression de Hairless Proteins und Verfahren deren Benutzung
WO2001060326A3 (fr) Composition cosmetique ou pharmaceutique contenant une lactone sesquiterpenique
AU2002220654A1 (en) Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
BR0303347A (pt) Formulações de aerossol contendo ésteres de derivados de 3,17-diidroxi estratieno para deposição pulmonar
DK1330253T3 (da) Anvendelse af bioaktiv fraktion af kourindestillat ("Go-mutra") som en biofremmer for antiinfektionsmidler, anticancermidler og næringsmidler
WO2002100342A3 (en) (s, s'), (s, r')-amphetaminil, compositions and uses thereof
WO2002100346A3 (en) (r, r'),(r',s')-amphetaminil, compositions and uses thereof

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: ANGES MG INC., IBARAKI-SHI, OSAKA, JP

Owner name: MORISHITA, RYUICHI, SUITA-SHI, OSAKA, JP

8364 No opposition during term of opposition